EcoDrugPlus

Bdnf/nt-3 Growth Factors Receptor

Ensembl ID : ENSMZEG00005004526
Gene Symbol: LOC101467169
2 Cross references
204 Possible Orthologues:

Bruton Tyrosine Kinase

Ensembl ID : ENSMZEG00005008512
Gene Symbol: BTK
3 Cross references
204 Possible Orthologues:

C-C Chemokine Receptor Type 9

Ensembl ID : ENSMZEG00005019447
Gene Symbol: LOC101478668
3 Cross references
188 Possible Orthologues:

C-C Motif Chemokine Receptor 9

Ensembl ID : ENSMZEG00005018603
Gene Symbol: CCR9
3 Cross references
193 Possible Orthologues:

C-X-C Chemokine Receptor Type 2

Ensembl ID : ENSMZEG00005016218
Gene Symbol: LOC101482159
2 Cross references
274 Possible Orthologues:

C-X-C Motif Chemokine Receptor 4

Ensembl ID : ENSMZEG00005012580
Gene Symbol: CXCR4
3 Cross references
201 Possible Orthologues:

C-Reactive Protein

Ensembl ID : ENSMZEG00005014456
Gene Symbol: LOC101486301
2 Cross references
359 Possible Orthologues:

Cf Transmembrane Conductance Regulator

Ensembl ID : ENSMZEG00005013754
Gene Symbol: CFTR
3 Cross references
214 Possible Orthologues:

D(4) Dopamine Receptor

Ensembl ID : ENSMZEG00005016455
Gene Symbol: LOC101473958
3 Cross references
181 Possible Orthologues:

D(4) Dopamine Receptor

Ensembl ID : ENSMZEG00005022552
Gene Symbol: LOC101486227
3 Cross references
165 Possible Orthologues:

Dna Methyltransferase 1

Ensembl ID : ENSMZEG00005018912
Gene Symbol: DNMT1
3 Cross references
210 Possible Orthologues:

Dna Topoisomerase 1

Ensembl ID : ENSMZEG00005010072
Gene Symbol: LOC101483346
3 Cross references
207 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).